The prevention and treatment of cytomegalovirus infection in haematopoietic stem cell transplantation
- First Online:
- Cite this article as:
- Tuthill, M., Chen, F., Paston, S. et al. Cancer Immunol Immunother (2009) 58: 1481. doi:10.1007/s00262-009-0722-7
- 240 Downloads
Allogeneic haematopoietic stem cell transplantation (HSCT) is an intensive medical treatment involving myeloablative chemo-radiotherapy followed by stem cell rescue using allogeneic haematopoietic stem cells harvested from HLA-matched donors, which is primarily used for the treatment of haematological malignancies. Cytomegalovirus (CMV) infection is one of the major causes of morbidity and death after HSCT. This focused research review highlights the advances made with research into CMV in the HSCT setting. It provides the reader with an overview of current CMV research into the prevention and management of CMV infection.